Rapid Lateral Flow Assay Detects Several Viral Fevers Simultaneously
|
By LabMedica International staff writers Posted on 10 Mar 2015 |

Image: The diagnostic system is based on triangular silver nanoparticles that display different colors depending on their size (Photo courtesy of the Massachusetts Institute of Technology).
A team of biomedical engineers has developed a rapid diagnostic test that is able to detect several viruses such as Ebola, dengue fever, and yellow fever simultaneously from a single sample of patient's serum.
Investigators at the Massachusetts Institute of Technology (Cambridge, MA, USA) and Harvard Medical School (Boston, MA, USA) used a novel class of silver nanoparticles to drive a paper-based lateral flow assay. Lateral flow assays are commonly used to detect such pathogens as Rotavirus, adenovirus, Streptococcus A and B, and gonorrhea and in rapid pregnancy tests.
The investigators extended the usefulness of the lateral flow approach by incorporating antibodies bound to different colored nanoparticles. In the current version of the assay, following a 10 minute incubation, an orange band indicates the presence of yellow fever virus, a red band indicates Ebolavirus, and a green band indicates dengue fever virus.
The investigators expect that their new rapid test will complement more definitive diagnostic technologies, such as PCR. "If you are in a situation in the field with no power and no special technologies, if you want to know if a patient has Ebola, this test can tell you very quickly that you might not want to put that patient in a waiting room with other people who might not be infected," said senior author Dr. Lee Gehrke, professor of microbiology and immunology at Harvard Medical School. "That initial triage can be very important from a public health standpoint, and there could be a follow-up test later with PCR or something to confirm."
This type of diagnostic testing device is readily customizable to detect other infectious diseases, by linking the silver nanoparticles to different antibodies. "Thankfully the Ebola outbreak is dying off, which is a good thing, but what we are thinking about is what is coming next," said Dr. Gehrke. "There will undoubtedly be other viral outbreaks. It might be Sudan virus, or it might be another hemorrhagic fever. What we are trying to do is develop the antibodies needed to be ready for the next outbreak that is going to happen."
The rapid diagnostic test for multiple viral fevers was described in the February 12, 2015, online edition of the journal Lab on a Chip.
Related Links:
Massachusetts Institute of Technology
Harvard Medical School
Investigators at the Massachusetts Institute of Technology (Cambridge, MA, USA) and Harvard Medical School (Boston, MA, USA) used a novel class of silver nanoparticles to drive a paper-based lateral flow assay. Lateral flow assays are commonly used to detect such pathogens as Rotavirus, adenovirus, Streptococcus A and B, and gonorrhea and in rapid pregnancy tests.
The investigators extended the usefulness of the lateral flow approach by incorporating antibodies bound to different colored nanoparticles. In the current version of the assay, following a 10 minute incubation, an orange band indicates the presence of yellow fever virus, a red band indicates Ebolavirus, and a green band indicates dengue fever virus.
The investigators expect that their new rapid test will complement more definitive diagnostic technologies, such as PCR. "If you are in a situation in the field with no power and no special technologies, if you want to know if a patient has Ebola, this test can tell you very quickly that you might not want to put that patient in a waiting room with other people who might not be infected," said senior author Dr. Lee Gehrke, professor of microbiology and immunology at Harvard Medical School. "That initial triage can be very important from a public health standpoint, and there could be a follow-up test later with PCR or something to confirm."
This type of diagnostic testing device is readily customizable to detect other infectious diseases, by linking the silver nanoparticles to different antibodies. "Thankfully the Ebola outbreak is dying off, which is a good thing, but what we are thinking about is what is coming next," said Dr. Gehrke. "There will undoubtedly be other viral outbreaks. It might be Sudan virus, or it might be another hemorrhagic fever. What we are trying to do is develop the antibodies needed to be ready for the next outbreak that is going to happen."
The rapid diagnostic test for multiple viral fevers was described in the February 12, 2015, online edition of the journal Lab on a Chip.
Related Links:
Massachusetts Institute of Technology
Harvard Medical School
Latest Microbiology News
- Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
- Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
- Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
- Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
- Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
- New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever
- TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
- Automated Blood Culture System Speeds Detection of Bloodstream Infections
- New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
- Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
- Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Channels
Clinical Chemistry
view channel
FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
Chronic liver disease contributes substantially to mortality, and clinicians routinely screen adults with compensated cirrhosis for varices to prevent bleeding. However, endoscopy is invasive and reso... Read more
Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
Confirming pediatric inflammatory bowel disease (IBD) often requires imaging, endoscopy, and histopathology, prolonging time to diagnosis. Reliable, noninvasive blood tests remain an unmet need in routine... Read moreMolecular Diagnostics
view channel
Ultrasensitive ctDNA Assay Detects MRD in Breast, Colorectal, Renal Cancers
Minimal residual disease testing is increasingly used to guide adjuvant therapy and surveillance in solid tumors, but detecting very low levels of circulating tumor DNA remains challenging in routine practice.... Read more
Female-Specific RNA Biomarker May Help Explain Sex Differences in Immune Disease
Women show distinct susceptibility to infectious diseases and higher rates of autoimmune disorders, yet the molecular drivers remain unclear. This gap has limited sex-specific diagnostic and prognostic tools.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
New Cellular Biomarkers Correlate with Disease Severity in Sjögren Disease
Autoimmune disorders arise when immune responses target self-antigens, driving chronic inflammation and long-term morbidity. In primary Sjögren disease, inflammation of salivary and lacrimal glands leads... Read more
Airway Immune Signature May Predict Tuberculosis Progression Risk
Tuberculosis remains difficult to predict and prevent, despite widespread exposure worldwide. An estimated quarter of the global population has been infected with Mycobacterium tuberculosis, yet only a... Read morePathology
view channel
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read more
Study Highlights Biomarker Testing Delays in Lung Cancer Care
Timely biomarker results are critical to match lung cancer patients with targeted therapies or immunotherapies, yet many clinical pathways still delay testing after biopsy. Ordering responsibility, reimbursement... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Project Aims to Develop First Single-Cell Assay for ADC Therapies
Antibody-drug conjugates are expanding rapidly in oncology, intensifying the need for biomarker strategies that capture tumor heterogeneity at cellular resolution. Single-cell profiling can delineate cellular... Read more








